Rare Beauty's Cap Table — Why Selena Gomez Kept Founder Control

The Deal at a Glance

This page summarizes what is publicly known about the Selena Gomez / Rare Beauty transaction with Selena Gomez (founder-controlled); reported equity raise from Blackstone-aligned vehicles, including reported deal value, equity structure, year of close, and the key terms that practitioners refer back to when modeling comparable deals. Where a figure is reported in the trade press but not confirmed by a primary source, we mark it explicitly.

Why the Structure Matters

The technical structure of a celebrity equity deal often matters more than the headline price. In the case of Rare Beauty, the elements worth attention include the parties to the entity, the IP assignment, the operating-control split, the vesting schedule for any rolled equity, and the exit waterfall. Where the public record is incomplete, comparable transactions in the same category give a defensible starting point.

From a comparable-deals perspective, the Rare Beauty transaction sits inside a class of strategic moves where a major incumbent acquired or partnered with a celebrity-led brand to capture a demographic, a credibility halo, or a category-leadership position they could not manufacture in-house. The structural decisions we describe below are the ones that practitioners reuse — sometimes with attribution, often without.

What the Celebrity Actually Owned

One of the most under-discussed dimensions of celebrity equity deals is the question of what was actually owned at the time of the transaction. Did the celebrity hold founders' common stock, preferred stock, or only an option pool? Was there a separate IP-licensing entity that held name and likeness rights, distinct from the operating company? Were there founder-friendly provisions that survived the transaction, like board observation rights or anti-dilution protection?

For Selena Gomez and Rare Beauty, the answer to those questions shaped the post-transaction outcome more than the multiple did. Founders looking at this transaction as a comp should focus less on the price tag and more on the IP and ownership architecture beneath it.

Comparable Transactions

To contextualize Rare Beauty against the broader celebrity-brand transaction set, the closest comparables include other strategic-acquirer deals where a major incumbent paid a multiple of revenue or GMV to capture a celebrity-led brand. Within celebrity beauty, Fenty (Rihanna / LVMH), Rare Beauty (Selena Gomez), Rhode (Hailey Bieber / e.l.f.), and Kylie Cosmetics (Kylie Jenner / Coty) are the most-cited reference deals. Within celebrity spirits, Casamigos (George Clooney / Diageo) and Aviation Gin (Ryan Reynolds / Diageo) are the standard comps.

Each of these deals shows a different point on the structural spectrum — from full strategic acquisition to founder-controlled minority sale to royalty-style arrangements — and a careful read of where Rare Beauty sits on that spectrum is the first analytical step a comparable-pricing exercise should take.

Lessons for Founders and Celebrities Considering Similar Deals

Practitioners working on a celebrity-brand transaction in 2026 should take three lessons from the Rare Beauty deal. First, structure the operating company so the IP can be cleanly separated from the operating entity at exit — this preserves optionality whether the eventual transaction is a full sale, a JV, or an IPO. Second, vest celebrity equity on a schedule that matches the brand-build curve, not a one-size-fits-all SaaS schedule. Third, negotiate post-transaction creative-control provisions in writing and tied to specific deliverables, because verbal commitments at signing rarely survive integration.

For founder-led brands hoping to attract a celebrity partner using Rare Beauty as a precedent, the takeaway is that the celebrity's upside in this transaction was protected by the structure as much as by the brand performance. Anyone pitching an artist on equity should be ready to discuss those structural protections in technical detail at the first meeting.

Risk Factors and What Could Still Change

The Rare Beauty transaction sits inside a moving market. Several risk factors could shift the retrospective view of this deal. Multiples paid for celebrity-founded CPG have compressed and re-expanded multiple times since 2017, and a deal that looks like a peer benchmark today may look like an outlier in 2028. Regulatory scrutiny of influencer disclosure, FDA classification, and cross-border IP enforcement has tightened in every major market.

Internally, the operating performance of Rare Beauty post-transaction is the dimension most likely to revise the historical valuation. Strategic acquirers that fail to retain the founder-creator flywheel typically see brand revenue compress within 24-36 months of close, regardless of the upfront price paid.

The Verdict

The Rare Beauty deal will be referenced for the next decade as a structural template. Whether it ages as a premium-paid deal, a fair-value deal, or a discount-to-precedent deal will depend less on the trade-press headline at close and more on the operating outcomes that follow. For now, it sits in the small set of celebrity-brand transactions that practitioners use as a primary comp when pricing the next one.